Unusual gingival presentation following treatment with pembrolizumab

• Pembrolizumab is an FDA-approved immune checkpoint inhibitor that has shown promising results in cancer therapy. • Although generally well tolerated, pembrolizumab-associated oral adverse events have been documented in the literature. • Gingival ulceration and enlargement are a possible oral toxicity related to pembrolizumab.